§Why CasetextPricing

Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction

89 Fed. Reg. 77866 (Sep. 24, 2024)

Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction

Download PDF
Federal RegisterSep 24, 2024
89 Fed. Reg. 77866 (Sep. 24, 2024)
Document Headings

Document headings vary by document type but may contain the following:

  • the agency or agencies that issued and signed a document
  • the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  • the agency docket number / agency internal file number
  • the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

    • See the Document Drafting Handbook for more details.

    Department of Health and Human Services Food and Drug Administration
  • [Docket No. FDA-2015-E-2079]

    • AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice; correction.

    SUMMARY:

    The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 12, 2018, for the determination of the regulatory review period for the animal drug BRAVECTO. In accordance with the Court's order in Nissan Chemical Corp., et al. v. FDA, et al., No. 22-01598 (D.D.C), this document revises the SUPPLEMENTARY INFORMATION section of that notice by adjusting the start date of the testing phase for BRAVECTO. This notice supersedes the June 11, 2021, Federal Register document revising the February 12, 2018, notice.

    FOR FURTHER INFORMATION CONTACT:

    Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993, 301-796-3600.

    SUPPLEMENTARY INFORMATION:

    In the Federal Register of February 12, 2018 (83 FR 6033), in FR Doc. 2018-02761, in the first column, the first two paragraphs under the section “II. Determination of Regulatory Review Period,” the following revision is made on page 6034:

    FDA has determined that the applicable regulatory review period for BRAVECTO is 1,548 days. Of this time, 1,510 days occurred during the testing phase of the regulatory review period, while 38 days occurred during the approval phase. These periods of time were derived from the following dates:

    1. The date an exemption under section 512(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(j)) became effective: February 19, 2010. Pursuant to the Court's order in Nissan Chemical Corp., et al. v. FDA, et al., No. 22-01598 (D.D.C), the start date of the testing phase for BRAVECTO was February 19, 2010.

    Dated: September 19, 2024.

    Lauren K. Roth,

    Associate Commissioner for Policy.

    [FR Doc. 2024-21841 Filed 9-23-24; 8:45 am]

    BILLING CODE 4164-01-P